Secchi, O., Franchi, A. and Lunello, A. 2023. Comments to “Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy”. AboutOpen. 10, 1 (Jun. 2023), 82–86. DOI:https://doi.org/10.33393/ao.2023.2600.